Kambiz Kalantari, MD
Associate Professor of Medicine
MD: Shiraz University, Iran
434-924-5125 | Fax 434-924-5848 | firstname.lastname@example.org
My clinical interests include: (1) Hemodialysis vascular access. As director of the UVA Hemodialysis Vascular Access Program, I am constantly involved in development of new protocols and strategies to improve the rate of AVF and outcomes. We have established a multidisciplinary team to address this issue. One of our major achievements has been the development of the Hemodialysis Vascular Access Database. This database has provide a great opportunity for conducting quality improvement and clinical research projects in the filed of vascular access in dialysis; (2) Diabetic kidney disease, new treatments and diagnostic approaches; (3) Kidney ultrasonography and real-time ultrasound guidance for native and transplant kidney biopsies; (4) Bone disease in chronic kidney disease and secondary hyperparathyroidism. This is a relatively complicated field with many controversies among authorities on the goals of treatment and strategies used to achieve those goals; and (5) Care of patients with ESRD on hemodialysis.
My main research interests include: (1) ultrasound imaging of the kidney and the use of novel techniques of contrast enhanced ultrasound (CEU) in monitoring the changes in total and regional renal blood flow; (2) hemodialysis vascular access, specifically factors leading to failure to mature among the arteriovenous fistulae (AVF), and study of potential predictors of AVF maturation; and (3) pathways involved in the development and progression of diabetic kidney disease, especially the role of inflammatory molecules
Currently, I have an NIH Career Development Award (K23) to study the potential therapeutic effect of an experimental antiinflammatory agent in patients with type 2 diabetes and kidney disease. In this study I will be utilizing CEU to monitor the potential renal hemodynamic changes. I am currently involved in other investigator initiated (GCRC sponsored) and industry-sponsored clinical studies.
Kalantarinia K, Belcik JT, Patrie JT, Wei K. Real-time measurement of renal blood flow in healthy subjects using contrast enhanced ultrasound. Amer J Physiol Renal Physiol. 2009;297:F1129-1134.
Kalantarinia K. Novel imaging techniques in acute kidney injury. Curr Drug Targets. 2009;10:1184-1189.
Liu J, Kalantarinia K, Rosner MH. Management of lipid abnormalities associated with end-stage renal disease. Sem Dialysis. 2006;19(5):391-401.
Kalantarinia K, Okusa MD. The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease. Curr Diabetes Rep. 2006;6(1):8-16.
Kalantarinia K, Awad AS, Siragy HM. Urinary and renal interstitial concentrations of TNF-alpha increase prior to the rise in albuminuria in diabetic rats. Kidney Int. 2003;64(4):1208-1213.
Kalantarinia K, Siragy HM. The choice of antihypertensive drugs in patients with diabetes: angiotensin II and beyond. Curr Diabetes Rep. 2002;2(5):423-430.